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No other group of procaryotes has been so
embroiled in controversy and in establishing a
clear pathogenic niche as the mycoplasmas. Their
virulence determinants are undeniably complex,
and their unique biological properties likely chal-
lenge the host differently from typical bacterial
pathogens (1,2). Also, numerous Mycoplasma
species appear to comprise the commensal micro-
bial flora of healthy persons (3), and the association
of these mycoplasmas with disease complicates
the diagnosis and necessitates extensive and
highly specific serologic, nucleic acid, and epide-
miologic data. Nonetheless, mycoplasmas by
themselves can cause acute and chronic diseases
at multiple sites with wide-ranging complications
and have been implicated as cofactors in disease.
Recently, mycoplasmas have been linked as a
cofactor to AIDS pathogenesis and to malignant
transformation, chromosomal aberrations, the
Gulf War Syndrome, and other unexplained and
complex illnesses, including chronic fatigue syn-
drome, Crohn’s disease, and various arthritides
(4-8). Even with mounting evidence of their
pervasive and pathogenic potential, mycoplasmas
still evoke the image of a group of obscure or
impotent microorganisms. Yet they are evolu-
tionarily advanced procaryotes (9-11), and their
elite status as “next generation” bacterial patho-
gens necessitates new paradigms in fully under-
standing their disease potential.
Mycoplasmas, which lack cell walls but
possess distinctive sterol-containing plasma mem-
branes, are taxonomically separated from other
bacteria and belong to the class Mollicutes
(mollis, soft; cutis, skin). Mollicutes, a term that
includes the cell wall-less procaryotes assigned to
numerous genera under the class Mollicutes and
is frequently used interchangeably with myco-
plasmas, are unusual for other biological reasons
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as well. They are evolutionary descendants of the
low G+C containing gram-positive bacteria and,
through chromosome reduction, represent the
smallest self-replicating life forms. Their stream-
lined genome size, which illustrates extreme bio-
logical gene economy, imposes complex nutritional
requirements, such as dependence on external sup-
plies of biosynthetic precursors, including amino
acids, nucleotides, fatty acids, and sterols. This
limited coding capacity dictates for mycoplasmas
a parasitic way of life that few pathogenic micro-
organisms can claim. Therefore, the view that
pathogenic mycoplasmas can grow “independently”
requires an appreciation of their fastidious
nature and their intimate dependence upon the
host. Because of these properties, pathogenic
mycoplasmas are among the most difficult micro-
organisms to grow from clinical specimens and
remain frequent contaminants of primary and
continuous eucaryotic cell lines and tissue cul-
tures (12). In some instances, mycoplasma con-
tamination is obvious since infected eucaryotic
cells exhibit aberrant growth, metabolism, and
morphology. However, mycoplasmas often estab-
lish covert and chronic infections of target cells
that lead to either invalid and misleading data or
introduction of mycoplasmas or their products into
reagents dedicated to therapeutic or research pur-
poses. The recent emphasis on isolating viral agents,
such as human immunodeficiency virus (HIV)-1,
from human primary lymphocytic cells has also
demonstrated the frequent cocultivation of myco-
plasmas of human origin. Often, the unwanted
sources of exogenous mycoplasmas are serum
products and filter-“sterilized” (450 nm) solutions;
cross-contamination by already infected cell cul-
tures, viral stocks, or immunologic preparations;
breaks in technique, including aerosols from the
respiratory tract or by mouth pipetting; ignorance
of the mycoplasma problem; or scientific indifference.
Detailed up-to-date reviews describing the
biological and pathogenic properties of myco-
plasmas have been published (1,2,13,14). Our
intention here is to provide a concise historical
perspective of the role of mycoplasmas in human
disease; highlight the discoveries of new Myco-
plasma species and their association with human
illness and host conditions that present problems
in detection and treatment; describe selected
biological properties of mycoplasmas consistent
with their intimate host relationship and pos-
sible mechanisms of pathogenicity; and address
recent controversies associated with mycoplasmas
as emerging infectious agents. Renewed attention
to these issues may provide the impetus to
demystify mycoplasmas and improve their standing
as genuine, card-carrying pathogens.
Historical Perspectives
The earliest reports of mycoplasmas as infec-
tious agents in humans appeared in the 1930s
and 1940s. At that time, primary atypical
pneumonia was associated with an infectious agent
that because of its minute size and innate bio-
logical properties unknown at that time, passed
through bacteria-retaining filters, resisted penicillin
and sulfonamide therapies, and adapted to growth
in embryonated eggs and tissue culture cells.
Correlations between the etiologic agent of
“walking pneumonia” with viruses, L-forms, and
pleuropneumonialike agents (referred to as PPLOs
in publications and textbooks of that era) were
frequent and often misleading. Finally, definitive
studies in the early 1960s established Mycoplasma
pneumoniae as the singular cause of cold agglu-
tinin-associated primary atypical pneumonia (2).
Today M. pneumoniae remains an important cause
of pneumonia and other airway disorders, such as
tracheobronchitis and pharyngitis (13,14), and is
associated with extrapulmonary manifestations,
such as hematopoietic, exanthematic, joint, cen-
tral nervous system, liver, pancreas, and
cardiovascular syndromes (15).
The confusion associated with M. pneumoniae-
mediated infections has recurred many times
with other mycoplasmas, whose detection in clini-
cal specimens through culture, antibody, or
DNA-based testing is frequently dismissed as
“only mycoplasmas” even when they appear to be
the primary pathogens. Two mycoplasmas com-
monly found in the urogenital tracts of healthy
persons are Mycoplasma hominis and Ureaplasma
urealyticum. However, over the years, the patho-
genic roles of these mycoplasmas have been proven
in adult urogenital tract diseases, neonatal res-
piratory infections, and a range of other diseases
usually in immunocompromised patients (2).
Several recent examples illustrate the
increasing impact of Mycoplasma species on emer-
ging diseases. Mycoplasma fermentans strains
were first isolated from the lower genital tract of
both adult men and women in the early 1950s,
but their role in classic lower genital tract disease
has not been established (16). Reports in the 1970s
of M. fermentans in the joints of rheumatoid
arthritis patients and in the bone marrow of23 Vol. 3, No. 1—January-March 1997 Emerging Infectious Diseases
Synopses
children with leukemia raised expectations for its
pathogenic potential (17,18); these findings have
not been adequately confirmed. Sufficient evi-
dence, however, has accumulated recently to estab-
lish an important and emerging role for M.
fermentans in human respiratory and joint diseases.
For example, M. fermentans has been detected by
specific gene amplification techniques such as
polymerase chain reaction (PCR) in the synovial
fluid of patients with inflammatory arthritis, but
not in the joints of patients with juvenile or reac-
tive arthritis (19). In two other studies using
PCR,  M. fermentans was identified in the upper
respiratory tract of 20% to 44% of both healthy
and HIV-infected patients (20,21) and was asso-
ciated with acute respiratory distress syndrome
in nonimmunocompromised persons (22).
Mycoplasma genitalium was detected in the
urogenital tract of two patients with non-
gonococcal urethritis in 1981 (23), but for more
than a decade, very little was known about its host
distribution and pathogenicity. Early experi-
mental studies established that the organism
caused lower genital tract infections in both male
and female chimpanzees, with extensive urethral
colonization in males and apparent tissue inva-
sion, eventually leading to overt bacteremia (24).
However, the fastidious growth requirements of
M. genitalium from human hosts severely limited
further study until the advent of molecular
detection techniques. Specific sequences in the
140 kDa adhesin protein gene of M. genitalium
were selected as targets in a PCR-based detection
assay (25,26). Subsequent application of these
techniques in cases of acute nongonococcal
urethritis, not including those of patients colo-
nized or infected with Chlamydia trachomatis,
has provided mounting evidence for the involve-
ment of M. genitalium as an etiologic agent of
this disease (27-29). Also, M. genitalium has been
suspected in chronic nongonococcal urethritis and
pelvic inflammatory disease (30).
The discovery in 1988 of M. genitalium
strains in human nasopharyngeal throat specimens,
where they were frequently mixed with strains of
M. pneumoniae, not only changed dramatically
the concept of host distribution of M. genitalium
but also prompted critical questions about the
role of this mycoplasma in human respiratory
disease (31). However, the immunologic cross-
reactivity between M. genitalium and M. pneu-
moniae and the inability of most conventional
diagnostic serologic tests to conclusively identify
M. genitalium have complicated its delineation in
acute human respiratory disease. PCR assays
specific for the organism have detected M. genita-
lium in throat specimens of patients infected
with HIV-1 (32). However, these probes have not
been applied to control groups and patients in
outbreaks of acute respiratory disease and/or pneu-
monia to determine whether M. genitalium alone
is an etiologic agent in respiratory infections.
M. genitalium has been implicated as an
etiologic agent in certain human joint diseases.
This clinical correlation began with the obser-
vation of a mixed infection of M. pneumoniae and
M. genitalium in synovial fluid specimens of a
nonimmunocompromised patient after an acute
respiratory infection (33). A predominant role was
not established for either Mycoplasma species in
the initial respiratory disease or in the joint
manifestations, although evidence to implicate
postinfectious autoimmunity to both organisms
was described. These findings prompted a PCR
assay on synovial fluids from patients with
various arthritic syndromes, which presented
case reports on two of 13 patients with M.
genitalium detected in joint fluids (34).
Another area of emerging mycoplasmal
infections concerns immunodeficiency. Although
patients with congenital or acquired disorders of
antibody production are susceptible to a wide
variety of microbial infections, the unique suscep-
tibility of such patients to mycoplasmal infections
is a growing concern, especially considering the
number of occurrences, the types of mycoplasmas
involved, and the difficulties posed in the thera-
peutic management of such infections. In addition,
the increased use of prolonged or permanent
immunosuppressive chemotherapy required for
patients undergoing tissue or organ transplan-
tation or treatment of various malignant diseases
has also increased the risk for mycoplasmal
infections—from mycoplasmas that are part of
the normal human mollicute flora to those
acquired through animal contact.
The association between immunodeficiency
and mycoplasmal infections was first reported in
the mid 1970s in patients with primary hypogam-
maglobulinemia and infection with U. urealyticum,
M. pneumoniae, Mycoplasma salivarium, and  M.
hominis that localized in joint tissue, frequently
with destructive arthritis. Similar joint infections
in hypogammaglobulinemic patients with these
mycoplasmal species continue to be reported (35).
Since most of these mollicutes, with the possible24 Emerging Infectious Diseases Vol. 3, No. 1—January-March 1997
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exception of M. pneumoniae, occur as part of the
normal human flora, the origin of such joint
infections is considered endogenous. Patients
with hypogammaglobulinemia and other antibody
deficiencies are also especially susceptible to
mycoplasmal infections of the upper respiratory
and urinary tracts caused most frequently by M.
pneumoniae or U. urealyticum, respectively (36).
Mycoplasmal infections following organ trans-
plantation and immunosuppressive chemotherapy
were observed in the early 1980s, with both M.
hominis and U. urealyticum reported most often
(37-39). Although these infections most likely origi-
nated from the patient’s normal microbial flora, a
recent report of donor transmission of M. hominis
to two lung allograft recipients (40) suggests that
donor tissue may be a more important factor in
transplant infections than currently recognized.
While patients with antibody defects or those
receiving immunosuppressive drugs appear to be
the most susceptible to infections with mycoplasmas
present in healthy tissues, emerging evidence
indicates that contact with other mycoplasmas in
the environment is an important hazard. For
example, the direct isolation of a feline mycoplasma
(M. felis) from the joint of a hypogamma-
globulinemic patient with septic arthritis was
recently reported (41), with suspected transmis-
sion occurring through a cat bite 6 months before
the onset of arthritis. Other examples include
fatal septicemia caused by M. arginini, a common
animal mycoplasma, from blood and multiple tis-
sue sites in a slaughter house employee who had
advanced non-Hodgkin’s lymphoma and hypogam-
maglobulinemia (42), and a septicemic infection
with a canine mycoplasma (M. edwardii) in a patient
with advanced AIDS (M.K. York, pers. comm.).
One of the most critical aspects of myco-
plasmal infections in immunodeficient patients
is the frequent inability to control such infections
with appropriate broad spectrum antibiotics.
Although the tetracyclines and erythromycins
are effective chemotherapeutic agents for many
mycoplasmal infections, M. fermentans and M.
hominis strains are usually resistant to
erythromycin, and tetracycline-resistant strains
of M. hominis  and U. urealyticum have been
reported from the lower urogenital tract of
patients. However, these antibiotics and most
other broad spectrum agents have limited
mycoplasmacidal activity in vivo, and their
efficacy eventually depends on an intact host
immune system to eliminate the mycoplasmas.
Most hypogammaglobulinemic patients lack the
ability to mount a strong antibody response.
Guidelines for managing such mycoplasmal
infections in patients with immune defects
should include immediate in vitro testing of the
isolated mollicute against a wide range of anti-
biotics; expeditious administration of the antibiotic
by the most appropriate route (intravenously, if
warranted); prolonged therapy terminated only if
there is no rapid clinical or microbiological
response; and possibly administration of intra-
venous immunoglobulin (35,36). Clinical manage-
ment of mycoplasmal infections in transplant
patients is more difficult since immunoglobulins
may enhance graft or organ rejection. In the
absence of suitable mycoplasmacidal chemothera-
peutic agents, vigorous and sustained
chemotherapy with the most active antibiotic is
the current method of choice.
Mechanisms of Pathogenicity
Many mycoplasmal pathogens exhibit
filamentous or flask-shaped appearances and
display prominent and specialized polar tip
organelles that mediate attachment to host
target cells (43,44). These tip structures are
complex, composed of a network of interactive
proteins, designated adhesins, and adherence-
accessory proteins (Figure 1, [14,43]). These
proteins cooperate structurally and functionally
to mobilize and concentrate adhesins at the tip
and permit mycoplasmal colonization of mucous
membranes and eucaryotic cell surfaces, probably
through host sialoglycoconjugates and sulfated
glycolipids (Figure 2, [14,43,45]). It appears that
mycoplasmal cytadherence-related proteins
represent a superfamily of genes and proteins
that have been conserved through horizontal
gene transfer from an ancestral gene family. This
protein network resembles a specialized cyto-
skeletonlike apparatus, which may represent the
precursor to mammalian cytoskeletal and
extracellular matrixlike complexes (14). Other
Mycoplasma species lack distinct tip structures
yet are capable of cytadherence, and they may
use related genes or proteins or alternative
mechanisms of surface parasitism.
The family of mycoplasmal genes and proteins
involved in cytadherence has been studied most
extensively in M. pneumoniae (14,43,46-48).
Noncytadhering phenotypes that arise through
spontaneous mutation at high frequency have
been categorized into mutant classes on the basis25 Vol. 3, No. 1—January-March 1997 Emerging Infectious Diseases
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Figure 1. Transmission electron photomicrographs of the specialized tip organelle of cytadherence-positive M. pneumoniae demon-
strating a) truncated structure with nap, b) clustering of cytadherence-related proteins (P1, B, C, P30) at the tip based on immunolabeling
with ferritin and colloidal gold and crosslinking studies, and c) Triton X-100–resistant, cytoskeleton-like, structure with distinct bleb
and parallel filaments (14,43,45,46).
Figure 2. Transmission electron
photomicrograph of a hamster
trachea ring infected with  M.
pneumoniae (43). Note the
orientation of the mycoplasmas
through  their specialized tiplike
organelle, which permits close
association with the respiratory
epithelium.  M, mycoplasma; m,
microvillus; C, cilia.26 Emerging Infectious Diseases Vol. 3, No. 1—January-March 1997
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of distinct protein profiles. These noncytadhering
mycoplasmas cannot synthesize specific cytad-
herence-related proteins or are unable to stabilize
them at the tip organelle, which leads to abnormal
anatomical tip structures and avirulence (43).
Spontaneous reversion to the cytadhering pheno-
type is accompanied by the reappearance of the
implicated proteins, restoration of structurally
and functionally intact tips, and return of full
infectivity (43). Similar cytadherence-related
genes and proteins have been reported for M.
genitalium on the basis of biochemical, immuno-
logic, and genetic analyses (25,49,50). Furthermore,
striking similarities exist in the order of operons
that comprise the cytadherence-related genes and
the organization of these genes within each operon
of  M. pneumoniae and  M. genitalium (14,50,51).
These similarities reinforce the unexpected coiso-
lations of M. genitalium, along with M. pneu-
moniae, from the nasopharyngeal throat swabs of
patients with acute respiratory diseases and
from synovial fluids of patients with arthritis as
described in the previous section (31,33). The
isolation of M. pneumoniae from the human
urogenital tract (52) further suggests that these
mycoplasmas have evolved parasitic strategies
that include overlapping tissue tropisms as
determined by the genetic and chemical related-
ness of their cytadherence genes and proteins
(14,25,43,50,51). The recent use of transposon
mutagenesis to generate M. pneumoniae and M.
genitalium transformants displaying cytadherence-
deficient phenotypes should further clarify the
relationships between the cytadherence-related
genes and proteins and identify additional sites
previously unlinked to cytadherence (46,53).
An interesting feature of specific M.
pneumoniae and M. genitalium adhesins is their
multiple gene copy nature (14,43,54,55,56).
Although only one full-length copy of the adhesin
structural genes exists in adhesin-related
operons, precise regions of these adhesin genes
are detected as single genomic copies, while other
regions occur as closely homologous, but not
identical, multiple copies. In other words,
multiple truncated and sequence-related copies
of the adhesin genes are dispersed throughout
the genome, which could generate adhesin
variation through homologous recombination.
Consistent with this possibility is the existence of
restriction fragment length polymorphisms in
the adhesin genes of human clinical isolates of
M. pneumoniae and M. genitalium, reflected by
sequence divergence in the multiple-copy regions
of the adhesin genes (56-59). It appears that a
repertoire of partial adhesin-related gene regions
serves as a reservoir to regulate the structural
and functional properties of mycoplasmal
adhesins through recombination events, which
may lead to circumvention of the host immune
response. Mechanisms of phase and antigenic
variation are likely to occur in which mycoplasmal
adhesins exhibit altered specificities and affinities,
as determined by the organization of constant
and variable adhesin gene sequences. Therefore,
despite their small genomes, pathogenic myco-
plasmas facilitate DNA rearrangements through
repetitive gene sequences, thus promoting
genetic diversity and maximizing the coding
potential of their limited genomes. The immuno-
dominant epitopes of the mycoplasmal adhesins
appear not to be identical to the adherence-
mediating domains (13). The latter are in part
encoded by single copy regions of the adhesin
genes and are highly conserved, which reinforces
their essential role in mycoplasmal recognition of
host cell receptors and colonization (60,61). Host
immunoresponsiveness directed at the noncytad-
herence-mediating variable regions is unlikely to
generate effective cytadherence-blocking antibodies,
which may in part clarify the observed high
reinfection rates of patients. Thus, the grouping
of clinical isolates of M. pneumoniae into two
categories, on the basis of sequence divergence in
the multiple-copy regions of the adhesin gene (56-
59), along with the immune status of the
population, may explain the epidemiologic patterns
of M. pneumoniae reported over the years.
Another characteristic of the cytadherence-
related proteins is their proline-rich composition,
which markedly influences protein folding and
binding. Several reports have established the
importance of these proline-rich domains in myco-
plasmal cytadherence and virulence (47,48,62,63),
and recent evidence further suggests that myco-
plasmal peptidyl-prolyl isomerases, i.e., cyclo-
philins, are critical in regulating the conformation
and function of the mycoplasmal cytadherence-
related tip organelle, colony morphology, and
growth (14,64). In addition to this proline-rich
property, one of the most unusual features of the
adhesins is their extensive sequence homology to
mammalian structural proteins (1,14,33,43,47,48).
This molecular mimicry is especially interesting
since it has been suggested for decades that
mycoplasmas provoke an anti-self response that27 Vol. 3, No. 1—January-March 1997 Emerging Infectious Diseases
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triggers immune disorders, although the basis
for the induction has been elusive (65). Patients
with documented M. pneumoniae respiratory
infections demonstrate seroconversion to myosin,
keratin, and fibrinogen (33) and exhibit extrapul-
monary manifestations, such as exanthems and
cardiac abnormalities. Furthermore, a classic
example of bacteria-mediated autoimmune dis-
orders is the development of acute rheumatic
fever following streptococcal infection (66). Anti-
streptococcal antibodies reactive against  a-helical
coiled-coil regions of the M protein cross-react
with heart myosin, tropomyosin, and mycoplasmal
adhesins (14,66). In the latter case, these myco-
plasmal adhesins exhibit amino acid sequence
homologies with human CD4 and class II major
histocompatibility complex lymphocyte proteins,
which could generate autoreactive antibodies
and trigger cell killing and immunosuppression
(67,68). Also, mycoplasmas may serve as B-cell
and T-cell mitogens and induce autoimmune
disease through the activation of anti-self T cells
or polyclonal B cells. The multiorgan protean
manifestations of mycoplasmal infections in
humans are consistent with the pathogenesis of
autoimmunity. Furthermore, the ability of myco-
plasmas to induce a broad range of immuno-
regulatory events, mediated by cytokine production
and direct effects on macrophages, B and T cells,
and glial cells, is evidence that mycoplasmas
possess the attributes of primary mediators of
pathogenesis (1,2,12,69). For example, cytokine
production and lymphocyte activation may either
minimize disease through the activation of host
defense mechanisms or exacerbate disease through
lesion development (69,70). Also, a superantigen
derived from Mycoplasma arthritidis, a myco-
plasma pathogenic for rodents, induces arthritis
and chronic disease manifestations (69). It has
been suggested that related superantigen-like
molecules may exist in mycoplasmas of human
origin triggering autoimmune and other
inflammatory pathologies.
It appears that cytadherence is the initial
step in the virulence process of pathogenic
mycoplasmas (Figure 2) and precedes a spectrum
of subtle or overt host cell responses. In specific
instances, distinct cytopathology correlates with
the infecting Mycoplasma species, the number of
adherent mycoplasmas, the length of coincubation,
the induction of proinflammatory cytokines, and
the age and immune status of the patient. For
example, the exacerbation of clinical syndromes
may correlate with a history of mycoplasmal
infection as observed in patients with recurrent
M. pneumoniae exposures (2,13). Also, the
elevated expression of proinflammatory cytokines
associated with mycoplasmal disease patho-
genesis may coincide with the intensity of the
symptoms. In other cases, chronic disease or no
obvious signs or symptoms of disease accompany
mycoplasmal infection.
Other biological properties of mycoplasmas
have been implicated as virulence determinants
and include 1) generation of hydrogen peroxide
and superoxide radicals by adhering myco-
plasmas, which induces oxidative stress, including
host cell membrane damage; 2) competition for
and depletion of nutrients or biosynthetic
precursors by mycoplasmas, which disrupts host
cell maintenance and function; 3) existence of
capsule-like material and electron-dense surface
layers or structures, which provides increased
integrity to the mycoplasma surface and confers
immunoregulatory activities; 4) high-frequency
phase and antigenic variation, which results in
surface diversity and possible avoidance of
protective host immune defenses; 5) secretion or
introduction of mycoplasmal enzymes, such as
phospholipases, ATPases, hemolysins, proteases,
and nucleases into the host cell milieu, which
leads to localized tissue disruption and
disorganization and chromosomal aberrations;
and 6) intracellular residence, which sequesters
mycoplasmas, establishes latent or chronic states,
and circumvents mycoplasmicidal immune mecha-
nisms and selective drug therapies (1,2,71,72).
Whether pathogenic mycoplasmas enter and
survive within mammalian cells has been
debated for many years.  Consistent with this
possibility, mycoplasmas exhibit limited biosyn-
thetic capabilities; are highly fastidious and
dependent upon the host microenvironment and
complex culture medium for growth; have been
observed in intimate contact with mammalian
cell surfaces and within target cells; may be
capable of initiating fusion with host cells through
their cholesterol-containing unit membranes;
and survive long-term recommended anti-
microbial treatment in humans and tissue
cultures. Recent sightings of intact mycoplasmas
throughout the cytoplasm and the perinuclear
regions of tissue cells from infected patients and
in cell cultures, along with evidence that28 Emerging Infectious Diseases Vol. 3, No. 1—January-March 1997
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mycoplasmas are capable of long-term intra-
cellular survival and replication in vitro, offer an
additional dimension to the pathogenic potential
of mycoplasmas (4,14,72,73).
The Latest Controversies: Food for
Thought or the Twilight Zone
On the basis of the above information, the
virulence strategies displayed by mycoplasmas
are likely the summation of a multitude of bio-
logical activities (1). Since no obvious single or
group of mycoplasmal properties inextricably
correlates with disease manifestations, the proof
that mycoplasmas are card-carrying pathogens
necessitates thorough and highly specific micro-
biological, epidemiologic, and diagnostic criteria;
detailed descriptions of biochemical, genetic, and
immunologic characteristics that distinguish
virulent and avirulent mycoplasmas; and repro-
ducibility of the symptoms of disease in experi-
mental animal models or in the natural spread of
infection among susceptible populations. The
portfolio of available evidence concerning myco-
plasma-mediated disease pathogenesis is limited.
These scientific shortcomings precipitate miscon-
ceptions concerning mycoplasmas as singular
agents of infectious diseases, as putative cofactors
in the progression of other diseases, and as
universal contaminants of cell cultures. Clearly,
multiple pathways of interaction with target cells
appears to be the modus operandi of the Myco-
plasma species. With this conceptual scientific
framework as a background, five recently proposed
and controversial associations of mycoplasmas to
human diseases are worth noting.
AIDS
The role of mycoplasmas in accelerating the
progression of AIDS could not have begun under
more baffling and circuitous conditions. A
viruslike agent that arose through transfection of
NIH 3T3 cells with DNA from Kaposi sarcoma
tissues of AIDS patients was later shown to be
M. fermentans. The spotted history of M. fermentans
in rheumatoid arthritis and leukemia and its
frequent contamination of cell cultures, along with
its contemporary link to AIDS, have been
considerable impediments to overcome in its ele-
vation to pathogenic status. However, careful and
convincing independent studies by several labora-
tories have implicated M. fermentans as a cause
of systemic infections and organ failure in AIDS
patients (4,74). The isolation of M. fermentans
from blood and urine samples of HIV-infected
persons, its detection by PCR and immuno-
histochemistry in multiple tissue sites at various
stages of AIDS, and its ability to stimulate CD4+
lymphocytes and other immunomodulatory
activities implicate this Mycoplasma species as a
cofactor in AIDS. Consistent with this possibility,
M. fermentans has been shown to act syner-
gistically with HIV to enhance cytopathic effects
on human CD4+ lymphocytes. Coincident with
these studies, a new Mycoplasma species,
Mycoplasma penetrans, also has emerged as a
potential cofactor in AIDS progression (75,76).
Its isolation almost exclusively from the urine of
HIV-infected patients, the extraordinarily high
prevalence of antibodies against this mycoplasma
in HIV-infected patients and not in HIV-
seronegative persons, and its capacity to invade
target cells and activate the immune system of
HIV-infected patients at various stages of disease
correlate with a synergistic role with HIV. Other
mycoplasmas, including M. genitalium and
Mycoplasma pirum, have also been isolated from
AIDS patients and implicated as potential
cofactors. However, the proposed role of myco-
plasmas as infectious agents and cofactors in
AIDS-related disorders still remains a hypothesis
without definitive proof. If cofactors of HIV are
essential to the development of late stages of
HIV-mediated disease, mycoplasmas possess all
the prerequisite properties of the consummate
helper. Their ability to establish covert or overt
chronic and persistent infections with concomitant
activation of the immune system, stimulation of
cytokine production, and induction of oxidative
stress correlate with increased HIV replication
and disease progression. Are mycoplasmas
irrelevant to AIDS, or are the clinical and
microbiological correlations sufficient to imply
intimate relationships between HIV and
mycoplasmas, especially as the infected host
undergoes immunologic distress?
Malignant Transformation
As early as the mid-1960s, mycoplasma-
infected cell lines were associated with chromo-
somal aberrations, altered morphologies, and cell
transformation (77,78). These abnormal oncogenic
cell traits continued even after the apparent
elimination of mycoplasmas, and evidence implied
increased tumorigenicity of these transformed
cells in animals. This issue has been revisited in
studies demonstrating that long-term, persistent29 Vol. 3, No. 1—January-March 1997 Emerging Infectious Diseases
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mycoplasmal infection of mouse embryo cells
initiated a multistage cellular process that
resulted in irreversible cell transformation,
karyotypic alterations, and tumorigenicity in nude
mice (6). Do these oncogenic events associated
with mycoplasma-mammalian cell coincubation
relate to the ontogeny of human cancers?
Gulf War Syndrome
One of the most controversial current
medical issues is whether the multiple acute and
chronic symptoms found in veterans of the
Persian Gulf War were caused by chemical
exposure, infectious agents, or psychological
problems, or whether a Gulf War Syndrome
exists at all. The clinical illness comprises a
collection of symptoms, including chronic fatigue,
joint pain, headaches, and skin rashes. One study
suggests that pathogenic mycoplasmas are
responsible for a large number of cases among
veterans, on the basis of DNA hybridization and
the responsiveness of veterans to prolonged
antibiotic treatment (5). Even though the experi-
mental evidence is sparse and incomplete and
well-controlled and detailed studies by
independent laboratories are needed, if the Gulf
War Syndrome has infectious causes,
mycoplasmas with their requisite biological
credentials are potential candidates.
Crohn’s Disease
Several epidemiologic studies correlate
respiratory infections with exacerbation of
Crohn’s disease and other chronic inflammatory
bowel diseases (7,79). Acute onset gastrointestinal
symptoms in patients with these diseases are
accompanied by seroconversion to specific viral
or M. pneumoniae antigens. As indicated earlier,
mycoplasmas can elicit pleiotropic immune
responses and are difficult to eliminate in
patients despite appropriate antibiotic treatment.
Steroid therapy to control gastrointestinal
symptoms in these patients, along with the
multifaceted biological properties associated
with pathogenic mycoplasmas, may precipitate
the onset of acute exacerbations of chronic
inflammatory bowel disease.
Rheumatoid Arthritis and Other Human
Arthritides
The occurrence of various Mycoplasma and
Ureaplasma species in joint tissues of patients
with rheumatoid arthritis, sexually transmitted
reactive arthritis, and other human arthritides
can no longer be ignored (8). A clinical trial of
long-term (6 to 12 months) antibiotic (doxycycline)
therapy before cartilage destruction might prove
beneficial in managing such frequent and often
debilitating infections.
Extensive clinical and microbiological
evidence indicates that mycoplasmas alone can
elicit a spectrum of illness for which no other
agents are incriminated. The eradication of these
pathogenic mycoplasmas from various tissue
sites requires an intact and functional immune
system, although persons with fully competent
immune systems may have difficulty eliminating
mycoplasmas, even with recommended prolonged
drug therapy. Nonetheless, mycoplasmas are
still viewed as subordinates to other infectious
agents and are relegated to a category of
commensals that unwittingly cause disease in
patients whose immune systems offer little
resistance to microbial stress and overload.
The fundamental importance of mycoplasmas
in specific diseases of humans, animals, insects,
and plants is irrefutable, and their unique
biological properties are consistent with their
intimate association with host target cells. These
remarkable bacteria must continue to receive the
scientific attention of mycoplasmologists, cell
culturists, clinicians, immunologists, and DNA
sequencers who most recently are compiling
extensive databases that may eventually dissect
every approachable mycoplasmal element that
defines their biological and genetic being.
Nonetheless, mycoplasmas remain mysterious
and enigmatic, and the available data and
proposed hypotheses that correlate mycoplasmas
with disease pathogenesis range from definitive,
provocative, and titillating to inconclusive,
confusing, and heretical. Controversy seems to be
a recurrent companion of mycoplasmas, yet good
science and open-mindedness should overcome
the legacy that has burdened them for decades.
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